Skip to main content
. 2022 Oct 5;10(10):1662. doi: 10.3390/vaccines10101662

Table 2.

Surrogate neutralization for SARS-CoV-2 Omicron (B.1.1.529) BA. 2 in solid cancer patients.

Neutralization against Omicron (30% Cut-Off)
Positive Negative
Anti-RBD Ig > 210 U/mL Adequate response 2 35
Anti-RBD Ig < 210 U/mL Inadequate response 0 3
Total 2 38